BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation announced today the EKOS EkoSonic ® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The ...
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Responding to a recently released American College of Chest Physicians evidence-based clinical practice guidelines for antithrombotic and thrombolytic therapy (.pdf), EKOS® Corporation from Bothell, ...
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices Each year, approximately 350,000 patients in the United ...
BOTHELL, Wash.-- EKOS Corporation announced today the EKOS EkoSonic® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The EkoSonic® System, ...
Data from patients treated with the EKOS system also demonstrated a lower rate of cardiorespiratory decompensation or collapse (3.7% vs. 10.3%), in which inability of the heart to maintain adequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results